IYH:NYE-iShares U.S. Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 54.98

Change

-1.38 (-2.45)%

Market Cap

N/A

Volume

0.43M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-3.12 (-2.32%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-1.56 (-2.45%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-2.83 (-2.73%)

USD 0.90B
XHE SPDR® S&P Health Care Equipme..

-2.55 (-3.06%)

USD 0.16B
IDNA iShares Genomics Immunology an..

-0.39 (-1.91%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-2.77 (-2.75%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

-0.78 (-2.66%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.83 (-3.00%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-1.43 (-2.50%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.64 (-3.42%)

USD 0.01B

ETFs Containing IYH

RXD ProShares UltraShort Heal.. 10.32 % 0.77 %

+0.55 (+4.50%)

N/A
RXD ProShares UltraShort Heal.. 10.32 % 0.95 %

+0.55 (+4.50%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.65% 48% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.65% 48% F 29% F
Trailing 12 Months  
Capital Gain -10.54% 29% F 24% F
Dividend Return 0.91% 81% B- 19% F
Total Return -9.63% 29% F 21% F
Trailing 5 Years  
Capital Gain 28.40% 86% B+ 48% F
Dividend Return 7.10% 74% C 15% F
Total Return 35.50% 86% B+ 39% F
Average Annual (5 Year Horizon)  
Capital Gain 4.09% 76% C+ 52% F
Dividend Return 5.09% 76% C+ 47% F
Total Return 0.99% 79% B- 23% F
Risk Return Profile  
Volatility (Standard Deviation) 17.45% 48% F 56% F
Risk Adjusted Return 29.14% 71% C- 47% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.